I wonder why Novo chose oral Sema for the trial. It seems there's some risk that it's less effective then injectable (as it is for weight loss / A1C?), so they'd want to give themselves the best chance of a significant result by using injectable Sema for the alzheimer's research.
I wonder why Novo chose oral Sema for the trial. It seems there's some risk that it's less effective then injectable (as it is for weight loss / A1C?), so they'd want to give themselves the best chance of a significant result by using injectable Sema for the alzheimer's research.